(Can-C™ N-Acetylcarnosine) actually work to reverse cataracts?
it is now known that cataract is the result of elevating levels of "ascorbate
oxidation" or oxidative stress due in part to oxygen free
radicals in the eyes of humans and animals. This unchecked oxidation results in the cross
linking of lens proteins, which is a slow glycosylation process. Cross linking
of the lens proteins eventually causes a yellowing or browning pigmentation
of the lens or (lens opacification) limiting the amount of light that reaches
the retina, resulting in worsening vision.
This degenerative process
occurs and advances as the natural antioxidant supply in the eye diminishes.
Critical antioxidant supplies are continually being tapped from the eye, for
protection against; over exposure to ultraviolet light, against toxins and chemicals
present in the air we breathe, the food we eat, against the hours we spend looking
at our computer screens, and so on.
Researchers recently learned that the healthy eye contains
high levels of the natural antioxidant carnosine.
Interestingly the eyes of those suffering from degenerative ocular diseases
such as cataracts were found to be grossly deficient in this essential ocular
The prime ingredient
is a proprietary form of N-acetylcarnosine, a highly specific intraocular released
form of carnosine which acts as both a stabilizer and carrier for the di-peptide L-carnosine, safely delivering
it into the aqueous humour of the eye, (the fluid area surrounding the lens).
It is here, that the bio-identical antioxidant becomes most active in its ability
to act as a natural and highly effective anti-oxidant.
Important Note: Years
of research were spent to identify a specific purity level of N-acetylcarnosine (NAC) that that would ensure both safety and optimal results. This purity level
is highly proprietary and only the N-acetylcarnosine products with Dr. Babizhayevs'
approval should be applied to the eyes. Look for the following statement on the
box of any N-acetylcarnosine eye drop product prior to applying to the eyes. "Aproved
by Innovative Vision Products". N-Acetylcarnosine
(Can-C™) carries this statement
on every box. - click
Mark Babizhayev of Innovative Vision Products (IVP), also makes it quite clear that common L-carnosine if used in a non- approved
n-acetylcarnosine formulation will not be of much use in the treatment of senile-cataract.
This is because there are many synthesized "carnosines" and their biological
and medicinal activity strongly varies depending upon how and where they are sourced.
example, if carnosine is extracted from meat muscle substances,
the biological and anti-oxidant activity is very low. This is presumably due to
the contamination of the "pure" carnosine substance by heavy metal salts
and proteins and other related impurities. It is very complicated to effectively
purify carnosine chromatographically, as the compound chelates divalent metal
ions very heavily and the biological and anti-oxidant activities can not be regenerated
during the purification procedures. In conclusion,
there were many forms of carnosine, which were abandoned, in the Russian studies
because of their lack of anti-cataract and anti-oxidant ability in the human eye.
However, Innovative Vision Products (IVP), in conjunction with their Japanese
partner and manufacturer, have researched, developed and patented a highly specific
purity factor of n-acetylcarnosine which has excellent biological activity and
has been proven effective in controlled human lens studies. Only the Can-C™
formula was used in the clinical trials. click
So what is the difference between Carnosine, L-Carnosine and N-acetylcarnosine?
There are different forms
of carnosine; the best known is L-Carnosine and much has been published as to
its impressive antioxidant and anti-aging benefits. N-acetylcarnosine which
is a specific intraocular released form of carnosine is significantly different
from L-carnosine although related. In addition to the proprietary, highly specific
purity level of the n-acetylcarnosine that is used in Can-C™,
the acetylation process is what makes n-acetyl-carnosine
suitable and stable in the eye. Unfortunately L-carnosine by itself,
when applied topically, is easily broken down by a dipeptidase enzyme that is
present in blood plasma known as carnosinase, and
therefore is not deliverable into the aqueous humour of the eye. Furthermore,
there are indications that a topical eye application of L-carnosine by itself
may release the toxic compound, histamine, (which can severely promote oxidation
reactions and therefore could cause other eye-problems with long-term use. This
means that L-carnosine by itself is not suitable for eye-drop use as it is either
ineffective, or could even be damaging to some tissues over time.
The acetylation component
of IVP N-acetylcarnosine (Can-C™) makes it very stable and highly resistant
to carnosinase. Additionally this stabilized compound protects against oxidative
stress in the lipid phase of biological cellular membranes and in the aqueous
environment by a gradual intraocular turnover into L-carnosine
maintaining a longer active therapeutic concentration of carnosine directly
within the aqueous humour and the lens of the treated eye. Again the purity
level of this particular n-acetylcarnosine is critical to its effectiveness.
properties reverse cross lining of lens proteins.
against oxidative stress both in the lipid phase of cellular membranes
and in the aqueous environment.
structural proteins of the lens/ alpha-crystalline, from the
free-radical induced oxidation process.
and stable at the cellular level.